Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
An FDA-approved growth-hormone-releasing hormone analog — with one specific approved use, and a lot of off-label interest beyond it.
Tesamorelin is unusual on this page: it's a genuinely FDA-approved drug with real trial data — for one specific indication. Interest in it, though, runs well beyond that approval. This page covers both what's proven and what isn't.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone, the hypothalamic signal that tells the pituitary gland to release growth hormone. It was FDA-approved in 2010 as the first and only GHRH analog approved for an adult metabolic indication: reducing visceral (abdominal) fat in people with HIV-associated lipodystrophy. A newer once-weekly formulation (Egrifta WR) was later approved to reduce the treatment burden of daily injections.
Tesamorelin binds GHRH receptors in the pituitary, stimulating the body's own pulsatile release of growth hormone — rather than delivering growth hormone directly. That distinction matters clinically: it works with the body's natural feedback loops rather than overriding them, which is part of why it has a more favorable long-term safety profile than direct growth hormone administration.
In pooled Phase III trial data across more than 800 participants, tesamorelin reduced visceral adipose tissue by roughly 15% versus placebo over 26 weeks — the evidence base behind its specific approval. That trial population was people with HIV-associated lipodystrophy; using it for general fat loss, athletic performance, or anti-aging purposes is off-label, and the evidence for those uses is much thinner than the evidence for its approved indication.
Common side effects include joint pain, swelling (especially in hands/feet, from fluid retention), and injection-site reactions. Because it raises IGF-1, it requires caution in anyone with a history of active malignancy, and isn't appropriate without a provider evaluating pituitary function and cancer history first.
Tesamorelin is one of the few peptides on this page with a genuine FDA approval and real trial evidence — for a specific population. That's worth knowing if you're considering it for a different reason than lipodystrophy: the science is real, but the approval doesn't automatically extend to every use it's marketed for online.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense tesamorelin or any medication.